Evolution of the Average Target: Autolus Therapeutics plc

Evolution of the Average Target - Autolus Therapeutics plc

Evolution of the Target Price: Autolus Therapeutics plc

Evolution of the Target Price - Autolus Therapeutics plc

Changes in Analyst Recommendations: Autolus Therapeutics plc

0c3b7f33f35fb102952f1355c79a.O5qnrJPBKkhxzR51O41IlKCb5gZl5wC2bZ6QAy7EP3s.erfg4d2kWgQ-hksNDLs-_ZfTi0U9vnHjHefbblz8ci4L_Jf5_qxFPgC-Ww~c0921b45b182ab6086460487910574d8
31/03 Mizuho Cuts Price Target on Autolus Therapeutics to $10 From $12, Keeps Outperform Rating MT
13/01 Truist Adjusts Price Target on Autolus Therapeutics to $8 From $10, Maintains Buy Rating MT
13/01 Truist Cuts Price Target on Autolus Therapeutics to $8 From $10, Keeps Buy Rating MT
31/25/31 Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating MT
18/24/18 Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7 MT
15/24/15 Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13 MT
18/24/18 Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating MT
12/24/12 Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating MT
22/24/22 Needham Adjusts Autolus Therapeutics' Price Target to $8 From $7, Maintains Buy Rating MT
13/23/13 Goldman Sachs Raises Price Target on Autolus Therapeutics to $4.80 From $3.20, Maintains Neutral Rating MT
09/23/09 Deutsche Bank Initiates Coverage on Autolus Therapeutics With Buy Rating, $10 Price Target MT
17/23/17 Truist Securities Adjusts Price Target on Autolus Therapeutics to $9 From $6, Maintains Buy Rating MT
05/23/05 Wells Fargo Adjusts Price Target on Autolus Therapeutics to $6 From $8, Maintains Overweight Rating MT
27/23/27 Wells Fargo Assumes Autolus Therapeutics at Overweight With $8 Price Target MT
08/23/08 Mizuho Adjusts Price Target on Autolus Therapeutics to $12 From $18, Maintains Buy Rating MT
09/22/09 Needham Lowers Price Target on Autolus Therapeutics to $7 From $12, Maintains Buy Rating MT
23/22/23 Truist Securities Trims Autolus Therapeutics' Price Target to $10 From $11, Maintains Buy Rating MT
14/22/14 Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating MT
20/21/20 HC Wainwright Adjusts Autolus Therapeutics' Price Target to $11 From $13, Reiterates Buy Rating MT
24/21/24 Autolus Therapeutics : Goldman Sachs Adjusts Price Target on Autolus Therapeutics to $5.50 From $9.50, Maintains Neutral Rating MT
14/21/14 Autolus Therapeutics : Jefferies Lifts Autolus Therapeutics to Buy From Hold, Price Target to $12 From $6 MT
06/21/06 Autolus Therapeutics : Needham & Co Adjusts Autolus Therapeutics PT to $21 From $26, Maintains Buy Rating MT
10/21/10 Autolus Therapeutics : Redburn Downgrades Autolus Therapeutics to Neutral from Buy MT
29/21/29 Autolus Therapeutics : JPMorgan Downgrades Autolus Therapeutics to Neutral From Overweight, Adjusts Price Target to $9 From $24 MT
07/21/07 Autolus Therapeutics : HC Wainwright Adjusts Autolus Therapeutics' Price Target to $13 From $19, Keeps at Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+475.66%
-1.45%
+2.27%
-3.97%
-2.72%
+7%
-5.37%
+12.5%
-14.74%
-3.15%
Average +46.60%
Weighted average by Cap. -0.73%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.520USD
Average target price
8.750USD
Spread / Average Target
+475.66%
High Price Target
11.00USD
Spread / Highest target
+623.68%
Low Price Target
5.000USD
Spread / Lowest Target
+228.95%

Analyst Consensus Detail

Analyst consensus - Autolus Therapeutics plc

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Autolus Therapeutics plc
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock
  4. Consensus Autolus Therapeutics plc